ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

An Investigational Immuno-therapy Study of Nivolumab Compared to Temozolomide, Each Given With Radiation Therapy, for Newly-diagnosed Patients With Glioblastoma (GBM, a Malignant Brain Cancer)

ClinicalTrials.gov ID: NCT02617589

Public ClinicalTrials.gov record NCT02617589. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 17, 2026, 4:52 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized Phase 3 Open Label Study of Nivolumab vs Temozolomide Each in Combination With Radiation Therapy in Newly Diagnosed Adult Subjects With Unmethylated MGMT (Tumor O-6-methylguanine DNA Methyltransferase) Glioblastoma (CheckMate 498: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 498)

Study identification

NCT ID
NCT02617589
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Bristol-Myers Squibb
Industry
Enrollment
560 participants

Conditions and interventions

Conditions

Interventions

  • Nivolumab Drug
  • Radiotherapy Radiation
  • Temozolomide Drug

Drug · Radiation

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Feb 29, 2016
Primary completion
Jan 16, 2019
Completion
Mar 3, 2022
Last update posted
Mar 27, 2023

2016 – 2022

United States locations

U.S. sites
37
U.S. states
24
U.S. cities
34
Facility City State ZIP Site status
University of Alabama at Birmingham Birmingham Alabama 35294-3410
Local Institution - 0083 Phoenix Arizona 85013
Cedars Sinai Medical Center Los Angeles California 90048
Local Institution - 0019 Los Angeles California 90095-1769
Sutter Institute For Medical Research Sacramento California 95816
Sharp Memorial Hospital San Diego California 92123
The Regents of the University of California, San Francisco San Francisco California 94143-0372
Yale Cancer Center New Haven Connecticut 06520
Georgetown University Medical Center Washington D.C. District of Columbia 20007
University Of Miami Sylvester Comprehensive Cancer Center Miami Florida 33136
Moffitt Cancer Center Tampa Florida 33612
Emory University - Winship Cancer Institute Atlanta Georgia 30322
The University Of Chicago Chicago Illinois 60637
University Of Kansas Medical Center Westwood Kansas 66205
Norton Cancer Institute Louisville Kentucky 40202
Johns Hopkins University School Of Medicine Baltimore Maryland 21287
Dana-Farber Cancer Institute Boston Massachusetts 02215
Massachusetts General Hospital Boston Massachusetts 02215
Local Institution - 0006 Detroit Michigan 48202
Washington University School OF Medicine-Siteman Cancer Center St Louis Missouri 63110
JFK Medical Center Edison New Jersey 08820
Local Institution - 0064 Hackensack New Jersey 07601
Columbia University Medical Center (Cumc) New York New York 10032
Memorial Sloan Kettering Cancer Center New York New York 10065
Levine Cancer Institute Charlotte North Carolina 28204
Preston Robert Tisch Brain Tumor Center at Duke University Durham North Carolina 27710
Local Institution - 0010 Cleveland Ohio 44195
Local Institution - 0095 Columbus Ohio 43210
Local Institution - 0132 Allentown Pennsylvania 18103
Local Institution - 0007 Philadelphia Pennsylvania 19107
Medical University Of South Carolina Charleston South Carolina 29425
Local Institution - 0090 Chattanooga Tennessee 37404
Vanderbilt University Medical Center Nashville Tennessee 37232
University Of Texas Southwestern Medical Center Dallas Texas 75390-8852
University Of Texas Md Anderson Cancer Ctr Houston Texas 77030
Local Institution - 0068 Salt Lake City Utah 84112
Swedish Neuroscience Institute Seattle Washington 98122

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 88 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02617589, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Mar 27, 2023 · Synced May 17, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02617589 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →